29
Views
8
CrossRef citations to date
0
Altmetric
Review

Antimalarial compound identification and design: advances in the patent literature, 2000 – 2003

, &
Pages 1125-1138 | Published online: 25 Feb 2005
 

Abstract

World patents filed from 2000 to 2003 claiming specific in vitro or in vivo antimalarial activity are examined and compiled in this review in a format that allows comparison across different chemical classes or drug targets. The most over-represented classes include the 1-desoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase inhibitors and novel quinoline or artemisinin analogues. This finding can be linked to important trends in the clinical development of new antimalarial drugs. Patents disclosing novel classes of antimalarial drugs were scarce. This may mean that the target-directed screening effort in malaria has not yet come to fruition, has not been commercially exploited in an appropriate manner, or that next generation compounds in known drug classes are more viable commercial entities.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.